Moody's Investory Services gave a thumbs up to Takeda Pharmaceuticals, with an "Aa1" issuer rating, saying the company's outlook is stable and it is likely to remain strong financially following the its acquisition of Millennium Pharmaceuticals for $7.4 billion. Report [1]
Links:
[1] http://www.forbes.com/afxnewslimited/feeds/afx/2008/06/25/afx5150797.html